Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for ONCSQ.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2008. Start Trial.
Date Value
January 31, 2023 -0.0115M
October 31, 2022 0.00
July 31, 2022 0.00
April 30, 2022 0.00
January 31, 2022 -0.2449M
October 31, 2021 0.00
July 31, 2021 -0.0449M
April 30, 2021 -0.5047M
January 31, 2021 -0.25M
October 31, 2020 0.00
July 31, 2020 0.00
April 30, 2020 0.00
January 31, 2020 0.00
October 31, 2019 0.00
July 31, 2019 1.00M
April 30, 2019 3.240M
January 31, 2019 5.232M
October 31, 2018 13.73M
July 31, 2018 -0.004M
April 30, 2018 -23.28M
January 31, 2018 -0.0082M
October 31, 2017 0.00
July 31, 2017 -0.012M
April 30, 2017 0.00
January 31, 2017 0.00
Date Value
October 31, 2016 -0.0096M
July 31, 2016 -0.3943M
April 30, 2016 -0.0955M
January 31, 2016 -0.5798M
October 31, 2015 -0.4811M
July 31, 2015 -0.6695M
April 30, 2015 -0.1982M
January 31, 2015 -0.1301M
October 31, 2014 -0.4334M
July 31, 2014 -0.3584M
April 30, 2014 -0.0989M
January 31, 2014 -0.0438M
October 31, 2013 -0.0115M
July 31, 2013 -0.0978M
April 30, 2013 -0.0136M
January 31, 2013 -0.0032M
October 31, 2012 0.00
July 31, 2012 -0.0312M
April 30, 2012 -0.0031M
January 31, 2012 -0.0029M
October 31, 2011 -0.0173M
July 31, 2011 -0.0436M
April 30, 2011 -0.2677M
January 31, 2011 0.00
October 31, 2010 0.00

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. -8.529M
Alnylam Pharmaceuticals, Inc. -363.46M
Anika Therapeutics, Inc. -1.28M
Savara, Inc. 32.60M
Vericel Corp. -2.82M